DLP 16.11.

2019

No new efficacy studies of interest were found.

DLP 12.07.2019

No new efficacy studies of interest were found.

DLP 20.04.2019

No new efficacy studies of interest were found.

DLP 21.01.2019

1.
Mymensingh Med J. 2014 Jul;23(3):441-8.
Comparison between azithromycin and cefixime in the treatment of typhoid fever in children.
Begum B, Haque MA, Ahmed MS, Islam MN, Ahsan MM, Khan AH, Hasan MM, Akhtaruzzaman
M, Hossain MA, Khaleque MA, Choudhury AM, Khatun AA.

Abstract
An intervention study was carried out in the department of paediatrics of Mymensingh Medical College
Hospital, Mymensingh to compare the clinical efficacy of Azithromycin in the treatment of childhood
typhoid fever with that of cefixime for a period of one year from January 2011 to December 2011. A total
of 60 cases of typhoid fever were enrolled in to a randomized clinical trial and was divided into two
groups. The inclusion criteria of the cases were: Documented fever for more than 4 days plus two or more
of the following clinical features: toxic physical appearance, intestinal complaints, coated tongue, ceacal
gurgling, hepatomegaly and splenomegaly, diarrhoea and constipation plus positive Widal test and/or
blood culture positivity. Patients who had complication like GIT heamorrhage; intestinal perforaion and/or
shock were excluded from the study. Data were collected in a structured questionnaire. Azithromycin was
given at a dose of 10mg/kg/day for a period of 07 days Cefixime was given at a dose of 20mg/kg/day in
two divided dose for 14 days. The mean time of defervesence was 4.05+1.14 days with azithromycin and
3.41+0.95 with cefixime respectively. The minimum defervesence time was 02 days and maximum
defervesence time was 07 days. Clinical cure rate was 87% in azithromycin group and 93%
in cefixime group. No serious adverse effect was noted related to azithromycin and cefixime therapy
except nausea, vomiting, diarrhoea and jaundice. It was found that azithromycin is almost as effective
as cefixime in the treatment of typhoid fever.

Full text article: not available.

2.
Urologiia. 2013 Sep-Oct;(5):24, 26-8.
[The efficacy and safety of cefixime and amoxicillin/clavulanate in the treatment of asymptomatic
bacteriuria in pregnant women: a randomized, prospective, multicenter study].
[Article in Russian]
Rafal'skiĭ VV, Dovgan' EV, Kozyrev IuV, Gustovarova TA, Khlybova SV, Novoselova AV, Filippenko
NG, Likhikh DG.
Abstract
The study was aimed to the evaluation of efficacy and safety of cefixime and amoxicillin/clavulanate in the
treatment of asymptomatic bacteriuria in pregnant women. A prospective, multicenter, randomized study
that included 112 pregnant women with asymptomatic bacteriuria was performed. 58 women were
randomized in group 1 (cefixime [suprax solutab] 400 mg 1 time a day, 7 days), 54 women were included
in group 2 (amoxicillin/clavulanate [amoksiklav] 625 mg 3 times a day, 7 days). The average age of the
patients in group 1 was 25.2 +/- 6.6; in group 2--26.6 +/- 5.8 years. Physical examination, evaluation of
complaints, collection of data on adverse reactions, and bacteriological analysis of urine were performed
after enrollment in the study at visit 2 (day 10 +/- 1) and 3 (day 35 +/- 2). Comparable effectiveness
of cefixime and amoxicillin/clavulanate in the treatment of asymptomatic bacteriuria in pregnant women
was found. Eradication of the pathogen and sustained bacteriological response were observed in 94.8
and 92.7% of women treated with cefixime, and in 98.2 and 92.5% of women treated with
amoxicillin/clavulanate, respectively (P > 0.05). At the same time, the use of amoxicillin/clavulanate
compared with cefixime significantly higher was followed by the development of adverse reactions (13%
and 1.7; respectively; P = 0.02). Seven-day courses of cefixime at a dose 400 mg 1 time a day and
amoxicillin/clavulanate at a dose of 625 mg 3 times a day are high-effective treatment regimens for
asymptomatic bacteriuria in pregnant women in Russia. The use of amoxicillin/clavulanate is significantly
more often accompanied by the development of adverse reactions compared with cefixime.

Full text article: not available.

DLP 26.07.2018

1.
Vojnosanit Pregl. 2016 Jun;73(6):526-30.
Comparison of cefixime and amoxicillin plus metronidazole in the treatment of chronic periodontitis.
Dukić S, Matijević S, Daković D, Cutović T.

Abstract
BACKGROUND/AIM:
Despite significant advances in current medicine and improvement of overall health education, chronic
periodontitis is still a widespread disease. Losing teeth is the most serious complication of this particular
illness. The aim of this study was to examine patients with chronic periodontitis in order to evaluate the
efficacy of non-surgical therapy and combination of amoxicillin and metronidazole compared with
cefixime, which has not been so far used for the treatment of this disease.

METHODS:
Adult patients with chronic periodontitis (n = 90) underwent non-surgical periodontal treatment (zero-day)
and then randomly divided into three groups. The group I served as a control, the group II was
additionally treated with the combination of amoxicillin and metronidazole (for 7 days), while the group III
was treated with cefixime (also for 7 days). To assess the condition of periodontium before and seven
days after the therapy, four clinical parameters were used: gingival index (GI), bleeding on probing (BOP),
probing depth (PD) and clinical attachment level (CAL).

RESULTS:
On the day 7 after the beginning of the therapy, we found that all the three groups of patients had
statistically significant clinical improvement of three parameters: GI, BOP and PD, but not of the CAL.
However, the improvement of PD was only statistically, but not clinically significant. The improvement in
the control group of patients on the day 7 was 19% in BOP and 28% in GI; this improvement was
statistically highly significant after the addition of amoxicillin plus metronodazole (71% in BOP and 77% in
GI) or cefixime (62% in BOP and 82% in GI). Compared to the combination of amoxicillin and
metronidazole, cefixim was statistically significantly more effective for GI (p < 0.05), while for the other
three clinical parameters their effects were equal.

CONCLUSION:
The conjunction of amoxicillin plus metronidazole or cefixime to the causal treatment of patients with
chronic periodontitis led to statistically significant improvement in efficacy in relation to GI and BOP
parameters, while cefixime was statistically significantly more efficient than the combination of amoxicillin
and metronidazole for GI.

Full text article: